Enhanced circadian ACTH release in obese premenopausal women: reversal by short-term acipimox treatment

Petra Kok,1 Simon W. Kok,1 Madelon M. Buijs,1 Jos J. M. Westenberg,2 Ferdinand Roelfsema,3 Marijke Frölich,4 Marcel P. M. Stokkel,5 A. Edo Meinders,1 and Hanno Pijl1

Departments of 1General Internal Medicine, 2Radiology, 3Endocrinology and Metabolic Diseases, 4Clinical Chemistry, and 5Nuclear Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands

Submitted 14 June 2004 ; accepted in final form 20 July 2004


    ABSTRACT
 TOP
 ABSTRACT
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Several studies suggest that the hypothalamo-pituitary-adrenal (HPA) axis is exceedingly active in obese individuals. Experimental studies show that circulating free fatty acids (FFAs) promote the secretory activity of the HPA axis and that human obesity is associated with high circulating FFAs. We hypothesized that HPA axis activity is enhanced and that lowering of circulating FFAs by acipimox would reduce spontaneous secretion of the HPA hormonal ensemble in obese humans. To evaluate these hypotheses, diurnal ACTH and cortisol secretion was studied in 11 obese and 9 lean premenopausal women (body mass index: obese 33.5 ± 0.9 vs. lean 21.2 ± 0.6 kg/m2, P < 0.001) in the early follicular stage of their menstrual cycle. Obese women were randomly assigned to treatment with either acipimox (inhibitor of lipolysis, 250 mg orally four times daily) or placebo in a double-blind crossover design, starting one day before admission until the end of the blood-sampling period. Blood samples were taken during 24 h with a sampling interval of 10 min for assessment of plasma ACTH and cortisol concentrations. ACTH and cortisol secretion rates were estimated by multiparameter deconvolution analysis. Daily ACTH secretion was substantially higher in obese than in lean women (7,950 ± 1,212 vs. 2,808 ± 329 ng/24 h, P = 0.002), whereas cortisol was not altered (obese 36,362 ± 5,639 vs. lean 37,187 ± 4,239 nmol/24 h, P = 0.912). Acipimox significantly reduced ACTH secretion in the obese subjects (acipimox 5,850 ± 769 ng/24 h, P = 0.039 vs. placebo), whereas cortisol release did not change (acipimox 33,542 ± 3,436 nmol/24 h, P = 0.484 vs. placebo). In conclusion, spontaneous ACTH secretion is enhanced in obese premenopausal women, whereas cortisol production is normal. Reduction of circulating FFA concentrations by acipimox blunts ACTH release in obese women, which suggests that FFAs are involved in the pathophysiology of this neuroendocrine anomaly.

adrenocorticotropic hormone; spontaneous secretion; pituitary adrenal system; free fatty acids; obesity


THE ENDOCRINE ENVIRONMENT is a powerful regulator of body fat storage. For example, the hypothalamo-pituitary-adrenal (HPA) ensemble profoundly affects body composition in animals and humans. Glucocorticoid administration promotes body weight gain in rodents (19, 26, 77), and hypercortisolism in patients with Cushing's syndrome leads in visceral depots to excess fat, which is readily reversed by lowering plasma cortisol levels (45, 70).

Obese animal models are marked by an exceedingly active HPA ensemble. Genetically obese rodents have high levels of glucocorticoids (5, 6), adrenalectomy reduces body weight in these animals (12, 21), and subsequent corticosterone replacement restores the obese state (12, 22, 32, 61, 76). Adrenalectomy also attenuates diet-induced obesity. Removal of the adrenals reduces energy intake and adipose tissue weights in diet-induced obese rodents, which is reversed by glucocorticoid replacement (18, 36, 48, 62).

Various clinical studies suggest that the HPA axis is also hyperactive in human obesity. Both plasma ACTH and cortisol concentrations rise to higher levels in response to corticotropin-releasing hormone (CRH) administration alone or in combination with arginine vasopressin (AVP) in obese humans compared with normal-weight controls (51, 54, 69). Moreover, the cortisol response to ACTH is exaggerated in obese volunteers (29, 49, 53), and it has been reported that stress-induced cortisol secretion is increased in abdominally obese women (20). Furthermore, urinary free cortisol excretion appears to be elevated in abdominally obese humans (49, 53), whereas suppression of plasma cortisol levels by dexamethasone (43, 59) or hydrocortisone (35) is blunted. The cause of these endocrine perturbations remains elusive.

Considerable evidence obtained in experimental studies in rats shows that circulating free fatty acids (FFAs) are involved in the control of the HPA axis. Elevation of systemic or portal plasma FFA levels by intravenous lipid infusions enhances ACTH and cortisol secretion in rats (4, 74). Moreover, prolonged high-fat feeding raises circulating FFA levels and basal ACTH and cortisol concentrations in rodents (63). Circulating FFA concentrations are high in obese humans (15, 34).

Acipimox is a powerful inhibitor of lipolysis. Its antilipolytic action is probably mediated through suppression of intracellular cAMP levels, which inhibits cAMP-dependent protein kinase activity. This precludes proper association of hormone-sensitive lipase with triacylglycerol substrate in the lipid droplet of adipocytes, thereby hampering lipolysis and lowering circulating FFAs (13).

We hypothesized that the spontaneous secretory activity of the HPA axis is elevated and that lowering of circulating FFAs by acipimox would reduce HPA axis activity in obese humans.

To test these postulates, we measured 24-h spontaneous ACTH and cortisol release in lean and obese premenopausal women in the early follicular phase of their menstrual cycle. Obese women were studied twice, randomly assigned to short-term treatment with either acipimox (250 mg orally four times daily) or placebo in a double-blind crossover design.


    SUBJECTS AND METHODS
 TOP
 ABSTRACT
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Subjects

Eleven healthy, obese premenopausal women [body mass index (BMI) > 30 kg/m2] and 9 lean (BMI < 25 kg/m2) controls of similar age were recruited. All subjects enrolled in our study underwent medical screening, including medical history taking, physical examination, and standard laboratory hematology, blood chemistry, and urine tests. Acute or chronic disease, smoking, alcohol abuse, and use of medication were exclusion criteria. All participants were required to have regular menstrual cycles and did not use oral contraceptives. All subjects gave written acknowledgement of informed consent for participation.

Body fat distribution. The obese subjects were recruited so as to vary widely with respect to girth, whereas their BMI was required to fall within a relatively narrow range to enable the effect of regional body fat distribution on hormone release to be specifically judged. The total amount and location of excess body fat were determined in the obese women only. The percentage of total body fat mass (fraction of total body weight) was quantified using dual-energy X-ray absorptiometry (Hologic QDR4500) (7). Visceral and subcutaneous adipose tissue areas were assessed by MRI as described before (41), using a multislice fast-spin echo sequence (Gyroscan-T5 whole body scanner, 0.5 Tesla; Philips Medical Systems, Best, The Netherlands). MRI images were analyzed by two observers independently.

Drugs. The obese subjects were randomly assigned to 250 mg of acipimox or placebo in a double-blind crossover design by an independent investigator. Drug and placebo were taken four times daily (total 10 tablets) at 0700, 1300, 1900, and 0100 starting the day before admission until the end of the blood-sampling period.

Diet. To limit nutritional confounding, a dietician prescribed a personal eucaloric diet for each obese woman, taking basal energy requirements (calculated by the Harris-Benedict formula) and physical activity into account. The macronutrient composition of the diet was exactly the same for each obese woman on both study occasions. The diet consisted of bread meals prepared and supplied by the research center. Meals were served according to a fixed time schedule (breakfast at 0730, lunch at 1300, dinner at 1900) and were consumed within limited time periods. Lean women received a standarized eucaloric diet as well. No dietary restrictions were imposed on the obese women just before or between both study occasions.

Clinical Protocol

The protocol was approved by the Medical Ethics Committee of the Leiden University Medical Center. All subjects were admitted at 1600 to the Clinical Research Unit of the Department of General Internal Medicine in the early follicular stage of their menstrual cycle. Obese subjects were studied on two separate occasions with an interval of ≥8 wk, and apart from the subjects receiving acipimox or placebo treatment, the clinical set-up was exactly the same during both study occasions. Identical methodology was used to study HPA hormonal secretion in obese and normal-weight women. A cannula for blood sampling was inserted into an antecubital vein. The cannula was attached to a three-way stopcock and kept patent by a continuous saline infusion. Blood samples were taken with S-monovetten (Sarstedt, Etten-Leur, The Netherlands). One hour after admission, 24-h blood sampling started. Blood (1.2 ml) was collected at 10-min intervals for determination of plasma ACTH and cortisol concentrations. Blood samples (1.2 ml) for the measurement of plasma FFA levels were taken every 6 h in the obese subjects only. The total amount of blood drawn for the measurement of ACTH, cortisol, and FFA levels during each occasion was 187.5 ml. All subjects remained recumbent during the blood-sampling period, except for bathroom visits. Meals were served according to a fixed time schedule. Lights were switched off at 2300, and subjects were not disturbed by drawing of blood samples during their sleep (sleep monitoring by EEG was not performed). Subjects were awakened at 0100 for drug intake. Vital signs were recorded at regular time intervals.

Assays

Blood sample handling. Each tube, except the serum tubes (because of blood clotting), was immediately chilled on ice. All samples were centrifuged at 4,000 rpm at 4°C for 20 min within 60 min of sampling. Subsequently, plasma/serum was divided into separate aliquots and frozen at –80°C until assays were performed. Plasma ACTH concentrations were measured by immunoradiometric assay (IRMA) with a detection limit of 3 ng/l (Nichols Institute Diagnostics, San Juan Capistrano, CA). The intra-assay coefficient of variation ranged from 2.8 to 7.5%. The ACTH IRMA was calibrated against the standard obtained from the National Pituitary Agency (University of Maryland School of Medicine) and the National Institute of Arthritis, Diabetes, and Kidney Diseases. Plasma cortisol concentrations were measured by radioimmunoassay (RIA) with a detection limit of 25 nmol/l (DiaSorin, Stillwater, MN). The intra-assay coefficient of variation ranged from 2.0 to 4.0%. The cortisol RIA was calibrated against the Public Health Service Cortisol Reference standard.

FFA levels were determined using a NEFA-C Free Fatty Acid Kit (Wako Chemicals, Neuss, Germany). The detection limit was 30 µmol/l, and the inter- and intra-assay coefficients of variation were 1.1 and 2.6%, respectively. Basal estradiol concentrations were determined by RIA (Diagnostic Systems Laboratory, Webster, TX). The detection limit was 10 pmol/l, and the inter- and intra-assay coefficients of variation were 6.8 and 15.8%, respectively.

Calculations and Statistics

Deconvolution analysis. Multiparametric deconvolution analysis was used to estimate various kinetic and secretory parameters of spontaneous 24-h ACTH and cortisol plasma concentration time series data. Initial waveform-independent assessments of ACTH and cortisol secretion were created with Pulse 2, an automated pulse detection program. Subsequent analysis with a waveform-dependent multiparametric deconvolution method was performed as described previously, using a first-component half-life of 3.5 min, second-component half-life of 14 min, and relative contribution of the slow component to the total elimination of 0.67 for ACTH and a first-component half-life of 3.8 min, second-component half-life of 66 min, and relative contribution of the slow component to the total elimination of 0.67 for cortisol (66). This technique thus estimates the rate of basal release, the number and mass of randomly ordered secretory bursts, and the subject-specific half-life. The daily pulsatile secretion is the product of secretory burst frequency and mean secretory burst mass. Total secretion is the sum of basal and pulsatile secretion. Results are expressed per liter distribution volume. For the calculation of production rates per liter, ACTH distribution volume was estimated to amount to 40 ml/kg (65), and the distribution volume of cortisol was estimated to be 5.3 liters/body surface area (m2), which was calculated using the Dubois formula (37, 71). The relationship between plasma ACTH and cortisol concentrations was determined by cross-correlation analysis.

Approximate entropy. Approximate entropy (ApEn) is a scale- and model-independent statistic that assigns a nonnegative number to time series data, reflecting regularity of these data (56). We used normalized ApEn parameters of m = 1, r = 20%, and 1,000 for the amount of runs to test for regularity in 24-h plasma ACTH and cortisol concentration time series. Hence, this member of the ApEn family is designated ApEn (1, 20%). The ApEn metric evaluates the consistency of recurrent subordinate (nonpulsatile) patterns in a time series and thus yields information distinct from and complementary to deconvolution (pulse) analyses (67). Higher absolute ApEn values denote greater relative randomness of hormone patterns. Data are presented as normalized ApEn ratios, defined by the mean ratio of absolute ApEn to that of 1,000 randomly shuffled versions of the same series. Cross-ApEn was used to investigate joint regularity of the hormone pair ACTH-cortisol (55).

Statistical analysis. Means of cortisol and ACTH secretion parameters of lean and obese volunteers were compared using independent Student's t-test. The means of ACTH and cortisol secretion parameters in obese subjects during acipimox vs. placebo treatment were compared using Student's t-test for paired samples. Regression analysis was used to determine the correlation between BMI and daily ACTH and cortisol secretion in obese and normal-weight women. Stepwise multiple regression analysis, including percent body fat, subcutaneous fat area, and visceral fat area as independent variables, was used to determine the relationship between the sizes of various fat depots and diurnal ACTH and cortisol production. The same technique was employed to determine the effect of acipimox on ACTH and cortisol secretion in the obese subjects in relation to body fat distribution. Significance level was set at 0.05. Data are presented as means ± SE unless otherwise specified.


    RESULTS
 TOP
 ABSTRACT
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Subjects

Eleven obese and nine lean subjects were enrolled in this study. Mean age of both groups was similar (obese 36.6 ± 1.9 vs. lean 36.4 ± 2.0 yr, P = 0.971), whereas BMI was significantly different (obese 33.5 ± 0.9 vs. lean 21.2 ± 0.6 kg/m2, P < 0.001). All subjects were studied in the follicular phase of their menstrual cycle, and basal estradiol (E2) levels in plasma were similar in both groups (obese 190 ± 31 vs. lean 208 ± 66 pmol/l, P = 0.795). Body weight of the obese subjects remained stable from 3 mo before until the end of the study period.

Features of Spontaneous 24-h ACTH and Cortisol Secretion in Lean and Obese Women

Total ACTH production was clearly higher in the obese subjects. In particular, pulsatile production, burst frequency, and burst mass were enhanced, whereas basal secretion, half-life, and secretory half-duration were not significantly different. Cortisol kinetic parameters were similar in the obese subjects compared with age-matched lean controls, except half-life, which was slightly prolonged in the obese women. A graphic illustration of representative ACTH and cortisol concentration profiles and corresponding secretion profiles of one obese and one lean woman of similar age are presented in Fig. 1. Data of ACTH kinetic parameters of the obese and lean subjects are presented in Table 1 and Fig. 2. An overview of cortisol kinetics, as estimated by deconvolution analysis, is given in Table 2.



View larger version (41K):
[in this window]
[in a new window]
 
Fig. 1. Representative 24-h ACTH (A and B) and cortisol (C and D) concentration profiles (A and C) and corresponding diurnal secretion plots (B and D) of one lean ({bullet}) and one obese woman ({circ}). Lean woman age 33 yr, body mass index (BMI) 18.3 kg/m2; obese woman age 31 yr, BMI 39.4 kg/m2. ACTH concentration (24-h, ng/l) and corresponding secretion (ng·l–1·min–1) profiles. Cortisol concentration (24-h, nmol/l) and corresponding secretion (nmol·l–1·min–1) profiles.

 

View this table:
[in this window]
[in a new window]
 
Table 1. Twenty-four-hour ACTH secretory parameters

 


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 2. Features of diurnal ACTH secretion in obese women during placebo and acipimox treatment and in lean controls. Vd, distribution volume. Error bars of the box plot represent SE. *P < 0.05, obese vs. lean women; statistical analysis was performed using independent Student's t-test. **P < 0.05, placebo vs. acipimox obese women; statistical analysis was performed using paired-samples t-test.

 

View this table:
[in this window]
[in a new window]
 
Table 2. Twenty-four-hour cortisol secretory parameters

 
Effect of Acipimox on Spontaneous 24-h ACTH and Cortisol Secretion Parameters in Obese Women

Mean 24-h plasma FFA levels were reduced during acipimox treatment in all subjects (placebo 0.52 ± 0.04 vs. acipimox 0.40 ± 0.03 mmol/l, P = 0.005). Total ACTH production was significantly lower in the obese subjects during acipimox treatment (Fig. 2). In particular, peak frequency and pulsatile production were reduced, whereas basal secretion, half-life, and secretory half-duration were not affected. Data of ACTH secretory and kinetic parameters during acipimox and placebo treatment are presented in Table 1.

Acipimox did not affect cortisol kinetic and secretory parameters in the obese women. An overview of cortisol kinetics, as estimated by deconvolution analysis, during acipimox and placebo treatment is shown in Table 2.

Regularity of Plasma ACTH and Cortisol Concentration Time Series

ApEn ratios of plasma ACTH concentration time series were significantly higher in obese women compared with controls (0.56 ± 0.03 vs. 0.45 ± 0.04, respectively, P = 0.033), whereas the regularity of the 24-h cortisol concentration time series was similar in both groups (0.51 ± 0.03 vs. 0.52 ± 0.02, respectively, P = 0.738; Fig. 3). Cross-ApEn statistics showed that joint regularity of ACTH-cortisol hormone pairs was not significantly different between both groups (cross-ApEn ratio = 0.55 ± 0.03 vs. 0.49 ± 0.02, P = 0.143).



View larger version (11K):
[in this window]
[in a new window]
 
Fig. 3. Regularity of plasma ACTH and cortisol concentration time series in obese women during placebo and acipimox treatment and in lean controls. Higher absolute approximate entropy (ApEn) values denote greater relative randomness of hormone patterns. Data are presented as normalized ApEn ratios, defined by the mean ratio of absolute ApEn to that of 1,000 randomly shuffled versions of the same series. Vertical marks indicate median ApEn ratio in each group. Mean ApEn ratios of plasma ACTH concentration time series were significantly higher in obese women compared with controls, and the regularity of 24-h cortisol concentration time series was significantly less regular during acipimox treatment. *P < 0.05 obese vs. lean women; statistical analysis was performed using independent Student's t-test. **P < 0.05 placebo vs. acipimox obese women; statistical analysis was performed using paired-samples t-test.

 
Acipimox did not impact the orderliness of plasma ACTH concentration time series of the obese women (ApEn ratios: placebo 0.56 ± 0.03 vs. acipimox 0.66 ± 0.05, P = 0.092), whereas the regularity of 24-h cortisol concentration time series was significantly less regular during acipimox treatment (placebo 0.51 ± 0.03 vs. acipimox 0.56 ± 0.03, P = 0.009; Fig. 3). Cross-ApEn statistics showed that the joint regularity of ACTH-cortisol hormone pairs was lower during acipimox treatment (placebo vs. acipimox: cross-ApEn ratio 0.55 ± 0.03 vs. 0.63 ± 0.04, P = 0.029).

Correlation Between ACTH and Cortisol Concentration Time Series

Cross-correlation analysis revealed a high correlation between ACTH and cortisol concentration values, which was significantly higher in the obese women (obese: R = 0.85 ± 0.02 vs. lean: R = 0.77 ± 0.02, P = 0.016). ACTH was leading cortisol with a time lag of 10 min in both groups. Cross-correlation between ACTH and cortisol hormone pairs in the obese subjects was not significantly altered after acipimox treatment (placebo 0.85 ± 0.02 vs. acipimox 0.74 ± 0.06, P = 0.065). ACTH was leading cortisol with a similar time lag during both treatments (placebo 10 ± 2 vs. acipimox 30 ± 24 min, P = 0.426).

BMI vs. Daily ACTH and Cortisol Secretion in Lean and Obese Women

Both obese and lean subjects (n = 21) were included in the correlation analysis of BMI (range 18.3–39.4 kg/m2) vs. daily ACTH and cortisol production. A highly significant positive correlation was found for BMI vs. total ACTH production (R2 = 0.39, P = 0.003; Fig. 4). Also, BMI was positively related to peak frequency (R2 = 0.39, P = 0.003) and peak burst mass (R2 = 0.26, P = 0.022). Total cortisol secretion parameters were not related to BMI (total cortisol vs. BMI: R2 = 0.04, P = 0.413).



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 4. Correlation of BMI vs. diurnal ACTH secretion. Both obese and lean women (n = 21) were included in correlation analysis of BMI (range 18.3–39.4 kg/m2) vs. daily ACTH production. Total (24-h) ACTH production is calculated per liter distribution volume.

 
Body Fat Distribution vs. Daily ACTH and Cortisol Secretion and Effect of Acipimox in Obese Women

The obese subjects had a mean BMI of 33.5 (30.3–39.4) kg/m2. The mean of their percent total body fat mass (%total body wt) was 40.7 (36.9–46.3)%. Mean sizes of their visceral and subcutaneous fat area were 392 (274–539) cm2 and 1,326 (1,106–1,709) cm2, respectively. Multiple regression analysis, with percent total body fat mass and sizes of visceral and subcutaneous fat areas as independent variables, revealed that there was no significant correlation between any of these specific body composition parameters and total daily ACTH production, 24-h cortisol production, or decrease of total daily ACTH production during acipimox treatment. Additionally, regression analysis revealed that the reduction of FFA levels was not related to the reduction of ACTH secretion after acipimox treatment in the obese women [{Delta}FFA (mmol/l) vs. {Delta}ACTH (ng/24 h): R2 = 0.05, P = 0.550].


    DISCUSSION
 TOP
 ABSTRACT
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
This study delineates differences of spontaneous diurnal ACTH and cortisol secretion in obese and lean premenopausal women and evaluates the effects of acipimox, a powerful inhibitor of lipolysis, on the HPA hormonal ensemble in obese individuals.

The data show that daily ACTH secretion rates are substantially higher, whereas the ACTH release process is less regular (as evidenced by ApEn statistics) in obese than in lean women. Moreover, ACTH release rates correlate strongly with BMI, whereas the sizes of various fat areas (including visceral and subcutaneous fat depots) do not appear to be independently associated with ACTH production. The high ACTH secretion rate in obese subjects results from augmented peak frequency and secretory burst mass rather than enhanced basal secretion. Short-term treatment with acipimox apparently restores these kinetic anomalies (except release process randomness) to a large extent, which suggests that circulating FFA concentrations may be involved in the pathophysiology. In contrast, cortisol production is not different in obese and lean premenopausal women, and acipimox does not significantly affect the secretory dynamics of this hormone (except for a slight increase in secretory process randomness).

To our knowledge, this is the first study to estimate the secretion rates of pituitary-adrenal hormones in obese vs. lean humans by deconvolution analysis. A few previous papers reported that diurnal plasma ACTH concentrations are higher in obese individuals, whereas circulating cortisol levels are similar to those in lean controls (44, 52), which is in line with the results of the present study. Moreover, various other clinical studies showed that the incremental ACTH peak response to different exogenous stimuli is elevated in obese humans, which also corroborates our data (51, 54, 69).

The fact that ACTH release in obese women was blunted during acipimox treatment is in keeping with data from experimental studies showing that elevation of circulating FFA by Intralipid infusion raises plasma levels of ACTH (and corticosterone) (73, 74). It has been suggested that the acute stimulatory effect of FFA infusion on blood pressure in rodents is mediated by afferent vagal inputs modulating central {alpha}-adrenergic receptors (27). The hypothalamic paraventricular nucleus (PVN) contains a high density of both {alpha}1- and {alpha}2-adrenoreceptors, and there is considerable evidence that these receptors are involved in facilitating the secretion of CRH/AVP into the hypophysial portal system, which ultimately leads to stimulation of ACTH secretion (2, 3). Therefore, FFA-induced vagal inputs into PVN neurons may partake in the control of HPA activity. Alternatively, fatty acids are taken up by the brain (58) and exert direct effects on the electrical properties of neurons (46). Application of fatty acids into the ventromedial hypothalamus (VMH) inhibits neuronal firing in that area (63) and the VHM, in its turn, downregulates pituitary adrenal activity (16). Thus FFAs may directly reduce feedback restraint of the VMH on HPA activity at the hypothalamic level, ultimately leading to enhanced ACTH secretion by the pituitary gland. Collectively, these data suggest that FFAs enhance HPA output through effects on neuronal control systems in brain centers at the suprapituitary level and that circulating FFAs are involved in the pathophysiology of pituitary-adrenal hyperactivity in obese humans.

This inference is in apparent conflict with the results of a recent study, showing that elevation of circulating FFAs through intravenous infusion of a lipid-heparin solution reduces plasma ACTH and cortisol levels in (normal-weight) women (40). However, as those authors state in their discussion, the physiological relevance of their findings might be limited, because FFA plasma concentrations induced by Intralipid infusion were 5- to 10-fold higher than those usually found in (obese) humans. Also, because various types of fatty acids (i.e., long-chain/short-chain, saturated/unsaturated) may have a differential impact on neuronal membrane function (75), it seems unlikely that exogenous and endogenous lipids exert similar effects on the brain. Thus, although valuable in itself, the data reported by Lanfranco et al. (40) do not necessarily argue against the position that elevation of circulating FFAs is involved in the pathophysiology of ACTH hypersecretion in obese humans.

Interestingly, there was no correlation between the reduction of FFA levels and the decrease of ACTH production after acipimox treatment in the obese subjects. Therefore, it is conceivable that acipimox impacts ACTH release directly, through mechanistic pathways independent of its effect on plasma FFA levels. Acipimox is a nicotinic acid derivative that can bind to nicotinic acid receptors. Activation of various subtypes of nicotinic acid receptors modulates neuronal activity in a variety of different regions in the central nervous system (17, 25). To our knowledge, it is unknown whether neural circuits involved in the control of pituitary-adrenal activity contain nicotinic acid receptors. Also, it is unclear whether acipimox can cross the blood-brain barrier. However, we cannot exclude that acipimox affects ACTH secretion directly at the level of the brain.

In the present study, ApEn values of ACTH secretion data were significantly higher in the obese subjects compared with normal-weight controls. Higher ApEn values denote greater irregularity (or higher process randomness). Regularity of hormonal secretion patterns mirrors the net result of feedforward signaling and feedback restraint (68). Because it seems unlikely that negative feedback restraint by cortisol per se can explain the enhanced ACTH secretion of the HPA axis in the present study, because daily cortisol secretion was not altered, the feedforward drive activating the HPA axis may be increased in obese humans. CRH is one of the most potent hypothalamic secretogogues stimulating pituitary ACTH release. Thus elevated CRH might lead to increased randomness of ACTH release. Indeed, it has been demonstrated that CRH levels are elevated in hypothalamic areas and neurons involved in the regulation of HPA axis activity in the brains of obese rodents compared with their wild-type counterparts (5, 6). There is experimental evidence that leptin receptors are abundant in these CRH-containing neurons in the PVN of the rat brain (28), and intracerebroventricular leptin administration in animals enhances hypothalamic CRH content (23, 33, 60, 64). Human obesity is marked by elevated plasma leptin concentrations (14, 47), which may promote hypothalamic CRH release and thereby enhance ACTH release process irregularity. This might also explain the fact that circulating ACTH is only partially lowered by acipimox in obese women.

As alluded to earlier, our finding that diurnal plasma cortisol levels are normal in obese women in the face of increased ACTH concentrations corroborates other clinical studies (44) but remains unexplained. Although some studies report that urinary cortisol excretion is increased in (abdominal) obesity [implying that adrenal cortisol production is enhanced in the presence of normal circulating levels (50, 53)] and others suggest that 5{beta}-reductase activity (which converts cortisol to inactive cortisone) is increased in obese humans (72), plasma half-life of cortisol was slightly (but significantly) longer in our obese subjects, which obviously does not support the notion that obesity is associated with enhanced cortisol clearance. Thus the currently available clinical data suggest that the dynamics of the ACTH and cortisol ensemble are altered in obese humans, in the sense that cortisol release appears to be somewhat diminished in proportion to circulating ACTH. (In fact, even in absolute terms, cortisol production was slightly lower in our obese vs. normal-weight women, although the difference was not significant. Unfortunately, because of the relatively small group size, this study lacks the statistical power to significantly detect a 10% reduction of cortisol production, which could be physiologically relevant.) Various mechanistic explanations for this phenomenon were proposed, including insensitive adrenals (44) and reduced 21-hydroxylase activity [which would direct cortisol precursors toward androgen synthesis (29)]. Alternatively, enhanced sympathtic neuronal inputs into the adrenocortical cells may be involved. Evidence from experimental animal studies suggests that the sensitivity of the adrenal cortex to ACTH is centrally regulated by the suprachiasmatic nuclei via the autonomic nervous system (11). Sympathetic inputs particularly desensitize adrenocortical cells to ACTH action. Because obesity appears to be associated with increased sympathetic activity (31), this might explain the occurrence of relatively low cortisol levels in the face of elevated ACTH in the obese women enrolled in the present study. As a second alternative, it has also been described that leptin inhibits cortisol release directly at the adrenal gland (57). Leptin receptor expression was demonstrated in rat and human adrenal tissue, and exposure of primary cultured rat and human adrenal cells to leptin led to a dose-dependent decrease of ACTH-stimulated adrenocorticosteroid secretion, whereas no effect was found in adrenal cells obtained from db/db mice, which lack a functional leptin receptor (9, 24, 57). It has been reported that there is a strict reciprocal diurnal relation between leptin and cortisol levels in both rats and humans (8, 42). Also, reduced leptin levels are associated with enhanced cortisol secretion rates in narcoleptic humans (38, 39). Thus leptin-mediated peripheral inhibition of adrenal glucocorticoid production appears to be another possible mechanistic explanation for the relatively low cortisol secretion in the obese women. Conclusive evidence to support either one of these postulates has not been reported to date.

The mere fact that plasma cortisol levels are normal in obese humans may limit the (patho)physiological meaning of the current findings, as cortisol is considered to be the main messenger conveying HPA signals to target tissues. In this context, it is important to keep in mind that adipocytes express ACTH receptors and that ACTH is a powerful lipolytic hormone, at least in some species (10). Therefore, a high circulating ACTH concentration in itself may promote lipolysis in obese subjects. Also, melanocortin receptors are distributed widely throughout the body, which suggests that these peptides partake in the control of a variety of (partly unknown) physiological functions (1). Thus the exact implications of high plasma ACTH concentrations in the face of normal cortisol levels remain to be established. Furthermore, given the well-known sex and age effects on HPA activity (30), one has to take into account that these results are not necessarely applicable to men or postmenopausal women.

In conclusion, this study documents enhanced circadian ACTH release in obese premenopausal women in the face of normal circulating cortisol concentrations. Reduction of plasma FFA levels by acipimox blunts ACTH secretion in obese individuals, which suggests that circulating FFAs are involved in the pathophysiology of this neuroendocrine perturbation associated with obesity.


    ACKNOWLEDGMENTS
 
We gratefully acknowledge all the work performed by the following collaborators: E. J. M. Ladau-Eygenraam, E. C. Sierat-van der Steen, M. van Dyh-Besling, and H. G. Haasnoot-van der Bent.


    FOOTNOTES
 

Address for reprint requests and other correspondence: H. Pijl, Dept. of Internal Medicine (C4-83), Leiden Univ. Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands (E-mail: h.pijl{at}lumc.nl)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Abdel-Malek ZA. Melanocortin receptors: their functions and regulation by physiological agonists and antagonists. Cell Mol Life Sci 58: 434–441, 2001.[ISI][Medline]
  2. Al Damluji S, Iveson T, Thomas JM, Pendlebury DJ, Rees LH, and Besser GM. Food-induced cortisol secretion is mediated by central alpha-1 adrenoceptor modulation of pituitary ACTH secretion. Clin Endocrinol (Oxf) 26: 629–636, 1987.[ISI][Medline]
  3. Al Damluji S, Perry L, Tomlin S, Bouloux P, Grossman A, Rees LH, and Besser GM. Alpha-adrenergic stimulation of corticotropin secretion by a specific central mechanism in man. Neuroendocrinology 45: 68–76, 1987.[ISI][Medline]
  4. Benthem L, Keizer K, Wiegman CH, de Boer SF, Strubbe JH, Steffens AB, Kuipers F, and Scheurink AJ. Excess portal venous long-chain fatty acids induce syndrome X via HPA axis and sympathetic activation. Am J Physiol Endocrinol Metab 279: E1286–E1293, 2000.[Abstract/Free Full Text]
  5. Bestetti GE, Abramo F, Guillaume-Gentil C, Rohner-Jeanrenaud F, Jeanrenaud B, and Rossi GL. Changes in the hypothalamo-pituitary-adrenal axis of genetically obese fa/fa rats: a structural, immunocytochemical, and morphometrical study. Endocrinology 126: 1880–1887, 1990.[Abstract]
  6. Bina KG and Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology 71: 68–78, 2000.[CrossRef][ISI][Medline]
  7. Blake GM and Fogelman I. Technical principles of dual energy x-ray absorptiometry. Semin Nucl Med 27: 210–228, 1997.[ISI][Medline]
  8. Bornstein SR. Is leptin a stress related peptide? Nat Med 3: 937, 1997.[ISI][Medline]
  9. Bornstein SR, Uhlmann K, Haidan A, Ehrhart-Bornstein M, and Scherbaum WA. Evidence for a novel peripheral action of leptin as a metabolic signal to the adrenal gland: leptin inhibits cortisol release directly. Diabetes 46: 1235–1238, 1997.[Abstract]
  10. Boston BA. The role of melanocortins in adipocyte function. Ann NY Acad Sci 885: 75–84, 1999.[Abstract/Free Full Text]
  11. Buijs RM, Wortel J, Van Heerikhuize JJ, Feenstra MG, Ter Horst GJ, Romijn HJ, and Kalsbeek A. Anatomical and functional demonstration of a multisynaptic suprachiasmatic nucleus adrenal (cortex) pathway. Eur J Neurosci 11: 1535–1544, 1999.[CrossRef][ISI][Medline]
  12. Castonguay TW, Dallman MF, and Stern JS. Some metabolic and behavioral effects of adrenalectomy on obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 251: R923–R933, 1986.[Abstract/Free Full Text]
  13. Christie AW, McCormick DK, Emmison N, Kraemer FB, Alberti KG, and Yeaman SJ. Mechanism of anti-lipolytic action of acipimox in isolated rat adipocytes. Diabetologia 39: 45–53, 1996.[CrossRef][ISI][Medline]
  14. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, and Caro JF. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334: 292–295, 1996.[Abstract/Free Full Text]
  15. Couillard C, Bergeron N, Prud'homme D, Bergeron J, Tremblay A, Bouchard C, Mauriege P, and Despres JP. Postprandial triglyceride response in visceral obesity in men. Diabetes 47: 953–960, 1998.[Abstract]
  16. Dallman MF. Viewing the ventromedial hypothalamus from the adrenal gland. Am J Physiol Regul Integr Comp Physiol 246: R1–R12, 1984.[Abstract/Free Full Text]
  17. Dani JA. Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 49: 166–174, 2001.[CrossRef][ISI][Medline]
  18. Deshaies Y, Dagnault A, Lalonde J, and Richard D. Interaction of corticosterone and gonadal steroids on lipid deposition in the female rat. Am J Physiol Endocrinol Metab 273: E355–E362, 1997.[Abstract/Free Full Text]
  19. Drazen DL, Wortman MD, Schwartz MW, Clegg DJ, van Dijk G, Woods SC, and Seeley RJ. Adrenalectomy alters the sensitivity of the central nervous system melanocortin system. Diabetes 52: 2928–2934, 2003.[Abstract/Free Full Text]
  20. Epel ES, McEwen B, Seeman T, Matthews K, Castellazzo G, Brownell KD, Bell J, and Ickovics JR. Stress and body shape: stress-induced cortisol secretion is consistently greater among women with central fat. Psychosom Med 62: 623–632, 2000.[Abstract/Free Full Text]
  21. Freedman MR, Castonguay TW, and Stern JS. Effect of adrenalectomy and corticosterone replacement on meal patterns of Zucker rats. Am J Physiol Regul Integr Comp Physiol 249: R584–R594, 1985.[Abstract/Free Full Text]
  22. Freedman MR, Horwitz BA, and Stern JS. Effect of adrenalectomy and glucocorticoid replacement on development of obesity. Am J Physiol Regul Integr Comp Physiol 250: R595–R607, 1986.[Abstract/Free Full Text]
  23. Gardner JD, Rothwell NJ, and Luheshi GN. Leptin affects food intake via CRF-receptor-mediated pathways. Nat Neurosci 1: 103, 1998.[CrossRef][ISI][Medline]
  24. Glasow A and Bornstein SR. Leptin and the adrenal gland. Eur J Clin Invest 30, Suppl 3: 39–45, 2000.[CrossRef][ISI][Medline]
  25. Gotti C, Fornasari D, and Clementi F. Human neuronal nicotinic receptors. Prog Neurobiol 53: 199–237, 1997.[CrossRef][ISI][Medline]
  26. Green PK, Wilkinson CW, and Woods SC. Intraventricular corticosterone increases the rate of body weight gain in underweight adrenalectomized rats. Endocrinology 130: 269–275, 1992.[Abstract]
  27. Grekin RJ, Vollmer AP, and Sider RS. Pressor effects of portal venous oleate infusion. A proposed mechanism for obesity hypertension. Hypertension 26: 193–198, 1995.[Abstract/Free Full Text]
  28. Hakansson ML, Brown H, Ghilardi N, Skoda RC, and Meister B. Leptin receptor immunoreactivity in chemically defined target neurons of the hypothalamus. J Neurosci 18: 559–572, 1998.[Abstract/Free Full Text]
  29. Hautanen A and Adlercreutz H. Altered adrenocorticotropin and cortisol secretion in abdominal obesity: implications for the insulin resistance syndrome. J Intern Med 234: 461–469, 1993.[ISI][Medline]
  30. Heuser IJ, Gotthardt U, Schweiger U, Schmider J, Lammers CH, Dettling M, and Holsboer F. Age-associated changes of pituitary-adrenocortical hormone regulation in humans: importance of gender. Neurobiol Aging 15: 227–231, 1994.[CrossRef][ISI][Medline]
  31. Heuser IJ, Gotthardt U, Schweiger U, Schmider J, Lammers CH, Dettling M, and Holsboer F. Age-associated changes of pituitary-adrenocortical hormone regulation in humans: importance of gender. Neurobiol Aging 15: 227–231, 1994.[CrossRef][ISI][Medline]
  32. Holt S, York DA, and Fitzsimons JT. The effects of corticosterone, cold exposure and overfeeding with sucrose on brown adipose tissue of obese Zucker rats (fa/fa). Biochem J 214: 215–223, 1983.[ISI][Medline]
  33. Jang M, Mistry A, Swick AG, and Romsos DR. Leptin rapidly inhibits hypothalamic neuropeptide Y secretion and stimulates corticotropin-releasing hormone secretion in adrenalectomized mice. J Nutr 130: 2813–2820, 2000.[Abstract/Free Full Text]
  34. Jensen MD, Haymond MW, Rizza RA, Cryer PE, and Miles JM. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 83: 1168–1173, 1989.[ISI][Medline]
  35. Jessop DS, Dallman MF, Fleming D, and Lightman SL. Resistance to glucocorticoid feedback in obesity. J Clin Endocrinol Metab 86: 4109–4114, 2001.[Abstract/Free Full Text]
  36. Kang JS, Pilkington JD, Ferguson D, Kim HK, and Romsos DR. Dietary glucose and fat attenuate effects of adrenalectomy on energy balance in ob/ob mice. J Nutr 122: 895–905, 1992.[ISI][Medline]
  37. Kerrigan JR, Veldhuis JD, Leyo SA, Iranmanesh A, and Rogol AD. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab 76: 1505–1510, 1993.[Abstract]
  38. Kok SW, Meinders AE, Overeem S, Lammers GJ, Roelfsema F, Frolich M, and Pijl H. Reduction of plasma leptin levels and loss of its circadian rhythmicity in hypocretin (orexin)-deficient narcoleptic humans. J Clin Endocrinol Metab 87: 805–809, 2002.[Abstract/Free Full Text]
  39. Kok SW, Roelfsema F, Overeem S, Lammers GJ, Strijers RL, Frolich M, Meinders AE, and Pijl H. Dynamics of the pituitary-adrenal ensemble in hypocretin-deficient narcoleptic humans: blunted basal adrenocorticotropin release and evidence for normal time-keeping by the master pacemaker. J Clin Endocrinol Metab 87: 5085–5091, 2002.[Abstract/Free Full Text]
  40. Lanfranco F, Giordano R, Pellegrino M, Gianotti L, Ramunni J, Picu A, Baldi M, Ghigo E, and Arvat E. Free fatty acids exert an inhibitory effect on adrenocorticotropin and cortisol secretion in humans. J Clin Endocrinol Metab 89: 1385–1390, 2004.[Abstract/Free Full Text]
  41. Langendonk JG, Pijl H, Toornvliet AC, Burggraaf J, Frolich M, Schoemaker RC, Doornbos J, Cohen AF, and Meinders AE. Circadian rhythm of plasma leptin levels in upper and lower body obese women: influence of body fat distribution and weight loss. J Clin Endocrinol Metab 83: 1706–1712, 1998.[Abstract/Free Full Text]
  42. Licinio J, Mantzoros C, Negrao AB, Cizza G, Wong ML, Bongiorno PB, Chrousos GP, Karp B, Allen C, Flier JS, and Gold PW. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. Nat Med 3: 575–579, 1997.[ISI][Medline]
  43. Ljung T, Andersson B, Bengtsson BA, Bjorntorp P, and Marin P. Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. Obes Res 4: 277–282, 1996.[Abstract]
  44. Ljung T, Holm G, Friberg P, Andersson B, Bengtsson BA, Svensson J, Dallman M, McEwen B, and Bjorntorp P. The activity of the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system in relation to waist/hip circumference ratio in men. Obes Res 8: 487–495, 2000.[Abstract/Free Full Text]
  45. Lonn L, Kvist H, Ernest I, and Sjostrom L. Changes in body composition and adipose tissue distribution after treatment of women with Cushing's syndrome. Metabolism 43: 1517–1522, 1994.[ISI][Medline]
  46. Love JA, Saum WR, and McGee R Jr. The effects of exposure to exogenous fatty acids and membrane fatty acid modification on the electrical properties of NG108–15 cells. Cell Mol Neurobiol 5: 333–352, 1985.[ISI][Medline]
  47. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, and. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1: 1155–1161, 1995.[ISI][Medline]
  48. Mantha L, Palacios E, and Deshaies Y. Modulation of triglyceride metabolism by glucocorticoids in diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 277: R455–R464, 1999.[Abstract/Free Full Text]
  49. Marin P, Andersson B, Ottosson M, Olbe L, Chowdhury B, Kvist H, Holm G, Sjostrom L, and Bjorntorp P. The morphology and metabolism of intraabdominal adipose tissue in men. Metabolism 41: 1242–1248, 1992.[ISI][Medline]
  50. Marin P, Darin N, Amemiya T, Andersson B, Jern S, and Bjorntorp P. Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism 41: 882–886, 1992.[ISI][Medline]
  51. Pasquali R, Anconetani B, Chattat R, Biscotti M, Spinucci G, Casimirri F, Vicennati V, Carcello A, and Labate AM. Hypothalamic-pituitary-adrenal axis activity and its relationship to the autonomic nervous system in women with visceral and subcutaneous obesity: effects of the corticotropin-releasing factor/arginine-vasopressin test and of stress. Metabolism 45: 351–356, 1996.[ISI][Medline]
  52. Pasquali R, Biscotti D, Spinucci G, Vicennati V, Genazzani AD, Sgarbi L, and Casimirri F. Pulsatile secretion of ACTH and cortisol in premenopausal women: effect of obesity and body fat distribution. Clin Endocrinol (Oxf) 48: 603–612, 1998.[CrossRef][ISI][Medline]
  53. Pasquali R, Cantobelli S, Casimirri F, Capelli M, Bortoluzzi L, Flamia R, Labate AM, and Barbara L. The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J Clin Endocrinol Metab 77: 341–346, 1993.[Abstract]
  54. Pasquali R, Gagliardi L, Vicennati V, Gambineri A, Colitta D, Ceroni L, and Casimirri F. ACTH and cortisol response to combined corticotropin releasing hormone-arginine vasopressin stimulation in obese males and its relationship to body weight, fat distribution and parameters of the metabolic syndrome. Int J Obes Relat Metab Disord 23: 419–424, 1999.[CrossRef][Medline]
  55. Pincus S and Singer BH. Randomness and degrees of irregularity. Proc Natl Acad Sci USA 93: 2083–2088, 1996.[Abstract/Free Full Text]
  56. Pincus SM and Keefe DL. Quantification of hormone pulsatility via an approximate entropy algorithm. Am J Physiol Endocrinol Metab 262: E741–E754, 1992.[Abstract/Free Full Text]
  57. Pralong FP, Roduit R, Waeber G, Castillo E, Mosimann F, Thorens B, and Gaillard RC. Leptin inhibits directly glucocorticoid secretion by normal human and rat adrenal gland. Endocrinology 139: 4264–4268, 1998.[Abstract/Free Full Text]
  58. Rapoport SI. In vivo fatty acid incorporation into brain phosholipids in relation to plasma availability, signal transduction and membrane remodeling. J Mol Neurosci 16: 243–261, 2001.[CrossRef][ISI][Medline]
  59. Rosmond R, Dallman MF, and Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab 83: 1853–1859, 1998.[Abstract/Free Full Text]
  60. Schwartz MW, Seeley RJ, Campfield LA, Burn P, and Baskin DG. Identification of targets of leptin action in rat hypothalamus. J Clin Invest 98: 1101–1106, 1996.[Abstract/Free Full Text]
  61. Shimomura Y, Bray GA, and Lee M. Adrenalectomy and steroid treatment in obese (ob/ob) and diabetic (db/db) mice. Horm Metab Res 19: 295–299, 1987.[ISI][Medline]
  62. Storlien LH, James DE, Burleigh KM, Chisholm DJ, and Kraegen EW. Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity in rats. Am J Physiol Endocrinol Metab 251: E576–E583, 1986.[Abstract/Free Full Text]
  63. Tannenbaum BM, Brindley DN, Tannenbaum GS, Dallman MF, McArthur MD, and Meaney MJ. High-fat feeding alters both basal and stress-induced hypothalamic-pituitary-adrenal activity in the rat. Am J Physiol Endocrinol Metab 273: E1168–E1177, 1997.[Abstract/Free Full Text]
  64. Uehara Y, Shimizu H, Ohtani K, Sato N, and Mori M. Hypothalamic corticotropin-releasing hormone is a mediator of the anorexigenic effect of leptin. Diabetes 47: 890–893, 1998.[Abstract]
  65. Veldhuis JD, Iranmanesh A, Johnson ML, and Lizarralde G. Amplitude, but not frequency, modulation of adrenocorticotropin secretory bursts gives rise to the nyctohemeral rhythm of the corticotropic axis in man. J Clin Endocrinol Metab 71: 452–463, 1990.[Abstract]
  66. Veldhuis JD and Johnson ML. Deconvolution analysis of hormone data. Methods Enzymol 210: 539–575, 1992.[ISI][Medline]
  67. Veldhuis JD and Pincus SM. Orderliness of hormone release patterns: a complementary measure to conventional pulsatile and circadian analyses. Eur J Endocrinol 138: 358–362, 1998.[ISI][Medline]
  68. Veldhuis JD, Straume M, Iranmanesh A, Mulligan T, Jaffe C, Barkan A, Johnson ML, and Pincus S. Secretory process regularity monitors neuroendocrine feedback and feedforward signaling strength in humans. Am J Physiol Regul Integr Comp Physiol 280: R721–R729, 2001.[Abstract/Free Full Text]
  69. Vicennati V and Pasquali R. Abnormalities of the hypothalamic-pituitary-adrenal axis in nondepressed women with abdominal obesity and relations with insulin resistance: evidence for a central and a peripheral alteration. J Clin Endocrinol Metab 85: 4093–4098, 2000.[Abstract/Free Full Text]
  70. Wajchenberg BL, Bosco A, Marone MM, Levin S, Rocha M, Lerario AC, Nery M, Goldman J, and Liberman B. Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease. J Clin Endocrinol Metab 80: 2791–2794, 1995.[Abstract]
  71. Wang Y, Moss J, and Thisted R. Predictors of body surface area. J Clin Anesth 4: 4–10, 1992.[Medline]
  72. Westerbacka J, Yki-Jarvinen H, Vehkavaara S, Hakkinen AM, Andrew R, Wake DJ, Seckl JR, and Walker BR. Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab 88: 4924–4931, 2003.[Abstract/Free Full Text]
  73. Widmaier EP, Margenthaler J, and Sarel I. Regulation of pituitary-adrenocortical activity by free fatty acids in vivo and in vitro. Prostaglandins Leukot Essent Fatty Acids 52: 179–183, 1995.[ISI][Medline]
  74. Widmaier EP, Rosen K, and Abbott B. Free fatty acids activate the hypothalamic-pituitary-adrenocortical axis in rats. Endocrinology 131: 2313–2318, 1992.[Abstract]
  75. Yehuda S, Rabinovitz S, Carasso RL, and Mostofsky DI. The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol Aging 23: 843–853, 2002.[CrossRef][ISI][Medline]
  76. Yukimura Y, Bray GA, and Wolfsen AR. Some effects of adrenalectomy in the fatty rat. Endocrinology 103: 1924–1928, 1978.[Abstract]
  77. Zakrzewska KE, Cusin I, Sainsbury A, Rohner-Jeanrenaud F, and Jeanrenaud B. Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes 46: 717–719, 1997.[Abstract]




This Article
Abstract
Full Text (PDF)
All Versions of this Article:
287/5/E848    most recent
00254.2004v1
Alert me when this article is cited
Alert me if a correction is posted
Citation Map
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Google Scholar
Articles by Kok, P.
Articles by Pijl, H.
Articles citing this Article
PubMed
PubMed Citation
Articles by Kok, P.
Articles by Pijl, H.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.